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Abstract
Background: A recently published randomized control trial (RCT) showed a protection of the remnant
liver from ischemia-reperfusion (I/R) injury by pharmacological pre-conditioning with a volatile anaesthetic
in patients undergoing hepatic resection. Whether the continuous application of volatile anaesthetics
(pharmacological conditioning) also protects against I/R injury is unknown.
Methods: Consecutive patients undergoing liver resection with inflow occlusion from 2005–2007 were
included in the trial. Two groups of anaesthesia regimens with either continuous application of the volatile
anaesthetic sevoflurane (pharmacological conditioning) or continuous infusion of the intravenous (i.v.)
anaesthetic propofol (control group) were compared. Endpoints were serum-peak-aspartate aminotrans-
ferase (AST)/ alanine aminotranferease (ALT) levels, length of stay (LOS) and intensive care unit (ICU)
stays, and the occurrence of post-operative complications.
Results: Two hundred and twenty-seven patients were included. Pharmacological conditioning did not
protect the remnant liver from IR injury (adjusted difference for peak-AST:61.9 U/l, 95% confidence
interval (CI): -151.7–275.4 U/l, P = 0.568; peak-ALT:136.1 U/l, 95% CI: -113.7–385.9 U/l, P = 0.284) nor
reduce LOS (adjusted difference 0.9 days, 95% CI: -2.6–4.3 days, P = 0.622) or ICU stay (1.6 days, 95%
CI: -0.2–3.3 days, P = 0.079), and was not associated with reduced complication rates (adjusted OR 1.12,
95% CI:0.6–2.3, P = 0.761) compared with the control group.
Conclusion: In this retrospective study, continuous volatile anaesthesia in liver resection does not
provide protection of the remnant liver from IR injury compared with continuous i.v. anaesthesia.
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Introduction
A recently published randomized controlled trial (RCT) showed
that volatile anaesthesia confers protection against ischemia-
reperfusion (I/R) injury in patients undergoing hepatic resection
with inflow occlusion.1 I/R injury in the liver is caused by
clamping of the portal triad (inflow occlusion) that is used to
prevent intra-operative blood loss during hepatic resections.2–5
Both intra-operative blood loss and I/R injury are associated with
an increased risk of post-operative complications andmortality.6–9
The challenge is, therefore, to find a balance between reducing
intra-operative blood loss by using an inflow occlusion procedure,
and to minimize an I/R injury caused by the inflow occlusion.
Intermittent clamping of the portal triad as well as ischaemic
preconditioning has been shown to reduce I/R injury of the
remnant liver.10–15 We recently observed protection against
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ischaemic injury through pharmacological preconditioning with
sevoflurane, a commonly used volatile anaesthetic agent.1 While
ischaemic preconditioning is time-consuming and intermittent
clamping might lead to increased intra-operative blood loss, phar-
macological preconditioning is an easily applicable non-invasive
method.However, the timing between preconditioning and inflow
occlusion might be difficult. In addition, utilization of precondi-
tioning is not possible in emergency situations where hepatic
inflow occlusion cannot be preceded by pharmacological precon-
ditioning. An alternative could be the use of continuous volatile
anaesthetics throughout surgery (pharmacological conditioning).
The aim of this study was, therefore, to compare pharmacological
conditioning with sevoflurane with intravenous (i.v.) anaesthesia
performed with propofol with post-operative liver function as the
primary endpoint. We hypothesized that the continuous applica-
tion of volatile anaesthetics with sevoflurane (pharmacological
conditioning) would protect the remnant liver from I/R injury.
Materials and methods
Study design
Data were collected from a database with prospectively collected
data from all patients treated at the Swiss Hepato-Pancreato-
Biliary (HPB) Center at the University Hospital of Zurich, Swit-
zerland.1,16,17 For this analysis, we included consecutive patients
undergoing any type of liver resection with inflow occlusion for
benign or malignant diseases between 1 January 2005 and 31
December 2007 with an anaesthesia with either the i.v. applied
anaesthetic propofol or the volatile anaesthetic sevoflurane for the
entire surgical procedure. Control patients with propofol anaes-
thesia from a recently completed RCT1 were included as well.
Patients receiving pharmacological preconditioning with volatile
anaesthetics as well as patients with liver trauma or liver cirrhosis
were excluded. Also patients operated without inflow occlusion
during surgery were not considered for this study. Patients were
also excluded with a combination of volatile and i.v. anaesthetics
during liver surgery as a result of a high variability of dose and
ratio of these anaesthetics and resultant heterogeneity within this
group of patients (Fig. 1).
The study was approved by the institutional review board
for human studies and internationally registered at http://
clinicaltrials.gov (NCT01021228).
Anaesthesia
We compared two groups of patients who received either the
volatile anaesthetic sevoflurane (pharmacological conditioning)
or the i.v. anaesthetic propofol (control) (Fig. 2).
All patients received oral midazolam (7.5 mg) pre-operatively
for premedication. If desired and necessary, a thoracic epidural
anaesthesia was performed for post-operative pain control using
continuous application of ropivacaine (0.33% during surgery and
0.2% in the post-operative phase). Both groups received the same
induction of anaesthesia according to the standardized procedures
with fentanyl and atracurium as boluses according to clinical need
and remifentanil.
Allocation to one of the two anaesthesiological approaches was
entirely up to the discretion of the attending anaesthesiologist.
Anaesthesiologists were more likely to use conditioning anaesthe-
sia in patients with severe co-morbidities owing to its better
cardio-vascular tolerance compared with an i.v. anaesthetic. This
may have introduced confounding by indication that we tried to
minimize as described in the statistical analysis section below. The
pharmacological ‘conditioning group’ received a continuous vola-
tile anaesthesia with sevoflurane of 1.0–2.5 vol % (according to
age-related minimum alveolar concentration) during the liver
surgery. The ‘control group’ was anaesthetized with propofol
(plasma target concentration of 2–4 mg/ml) during the liver
surgery. Some of these patients had participated as control
patients in a previous RCT1 (Fig. 2).
Surgical procedure
The hepatic surgery was performed exclusively by surgeons spe-
cialized in HPB surgery according to international surgical stand-
ards for transection of liver parenchyma. For the liver resection, a
low central venous pressure (CVP) from 0 to 5 mmHg was
required to prevent a high intra-operative blood loss.14,18,19 The
parenchymal transections were done with the Kelly clamp crush-
ing technique3 under an inflow occlusion procedure.2–4,12 The
tourniquet technique around the portal triad was used as inflow
occlusion.14 The peri-operative management was performed
according to the surgical standards of the operating procedure
and to the standard care of the HPB centre.
Endpoints
The primary endpoint was the serum peak level of aspartate-
aminotransferase (AST) representing the IR injury of the liver
Exclusion:
-No inflow occlusion: n = 48
-Unknown if  inflow occlusion: n = 29
-RCT: n = 58
-Combination of  volatile and
 intravenous anaesthetics: n = 28
-Liver cirrhosis: n = 20
-Liver trauma: n = 2
-Age <18 years: n = 1
Eligble patients
n = 413
Included patients
n = 227
Conditioning
n = 141
Conditioning:            continuous volatile anaesthesia (n = 141 patients)
Control:                    continuous intravenous anesthesia (n = 86 patients)
Control
n = 86
Figure 1 Flow chart of the study design. RTC, randomized control
trial
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after a hepatic resection. Secondary endpoints were the serum
peak level of alanine aminotranferease (ALT), intra-operative
blood loss and lengths of hospital stay (LOS) as well as intensive
care unit (ICU) stay. According to the Clavien-Dindo classifica-
tion,20 mortality and morbidity were assessed as additional sec-
ondary endpoints. Post-operative complications were reported
and analysed for the presence of any complication from grade I to
grade V according to the Clavien-Dindo classification.20 We spe-
cifically assessed the occurrence of high relevant complications
such as grade III (requiring an intervention), IV (requiring ICU
stay) or V (death).
Statistical analysis
We did not have any missing variables for the primary and sec-
ondary endpoints. Regarding potential confounders, only 1.8%
of baseline ALT levels (all from the conditioning group) and
4.4% of baseline bilirubin levels (nine missing values in the con-
ditioning and one missing in the control group) were missing,
whereas the collection of all other factors was complete. Because
of the small amount of missing data, we decided to replace these
missing values by the median of the available data and did not
use more advanced techniques for missing data such as multiple
imputation.
In a first step of the analysis, we expressed the distribution of
variables using means and standard deviation (SD) for normally
distributed data, and medians and interquartile ranges for non-
normally distributed data. We tested data for normality with the
Kolmogorow–Smirnow test21 and performed quantile–quantile
plots of dependent variables.22
We compared the primary endpoint (serum peak level of
AST) between the two groups using simple linear regression
(without adjustment for confounders) and in the main analysis,
a multivariable linear regression model with peak serum AST
level as the dependent, and group allocation as the independent
variable. Potential confounders for which we adjusted in the
multivariable linear regression analyses were age, pre-operative
chemotherapy (yes/no), steatosis (yes = 5%/no = <5%), the
American Society of Anesthesiologists (ASA) physical status
classification, inflow occlusion time, and baseline AST/ALT and
bilirubin levels. We confirmed that the assumptions for linear
regression, i.e. the linearity of the relationship between depend-
ent and independent variables, homoscedasticity (constant
variance) of the errors and normality of the error distribution,
were met.23 We repeated these analyses for the secondary
endpoints. For the binary outcomes ‘any complication’ or
‘complications higher than IIIb’ (severe complication), we also
applied simple and multivariable models, but used logistic
regression analysis. For all results, we reported point estimates,
95% confidence intervals (CI) and P-values (0.05 considered
significant). We performed the statistical analyses using the
statistical program STATA (version 11; Stata Corp., College
Station, TX, USA).
Results
Study population
Two hundred and twenty-seven patients undergoing liver resec-
tions with inflow occlusion were included in the study (Fig. 1).
One hundred and forty-one patients received a continuous vola-
tile anaesthesia with sevoflurane (‘conditioning group’), whereas
86 patients received continuous i.v. anaesthesia with propofol
(‘control group’).
Patients’ characteristics are presented in Table 1. Patients of
the control group were younger [56.3 years (standard deviation
(SD) 12.7 years)] compared with the conditioning group [59.2
years (14.8 years)]. ASA score was higher in the conditioning
group (ASA score III or IV: 38.3%) compared with the control
group (16.3%). A steatosis degree of higher than 30% was more
often observed in patients of the control than in the conditioning
group (43% versus 33%). The presence of malignant disease was
similarly distributed in both groups (75.2–81.4%). Baseline AST
levels were higher in the conditioning group [mean 50.1 U/l
[47.8 U/l)]) than in the control group (mean 45.7 U/l [49.4 U/
l]). Operation time, duration of inflow occlusion and CVP
during surgery were similar among both groups (Table 2). Fifty
per cent of the patients in the conditioning group underwent a
major liver resection (3 Couinaud’s liver segments) and 42%
patients in the control group.
start of anaesthesia start of ischaemia end of ischaemia
inflow occlusion reperfusion
Conditioning
Control
Conditioning:           continuous volatile anesthesia (n = 141 patients)
Control:                    continuous intravenous anesthesia (n = 86 patients)
Sevoflurane
Propofol
end of anaesthesia
Figure 2 Study design
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Is there a protection against I/R injury of the liver
after hepatic resection by continuous application of
volatile anesthetics?
Compared with the control group with propofol anesthesia, a con-
tinuous application of volatile anesthetics (conditioning) did not
reduce serum peak levels of AST (adjusted difference for AST
61.85 U/l, 95%CI -151.66–275.38 U/l, P = 0.568). Serum peak
levels of ALT (adjusted difference 136.06 U/l, 95%CI -113.77–
385.90, P = 0.284) were also not significantly different (Table 3).
Does conditioning with the volatile anesthetic
sevoflurane improve the post-operative outcome?
Seventy-eight patients of the conditioning group (55.3%) and 42
patients of the control (48.8%) developed a post-operative com-
plication. Table 2 shows the frequency of post-operative compli-
cations. 30-days-mortality was higher in the conditioning group
(4.3%) than in the control group (2.3%).
No statistically significant differences in serum peak levels of
bilirubin or creatinine, blood loss, or length of hospital or ICU
stay were detected comparing the conditioning with the control
group (Table 3). Seventy-eight patients of the conditioning group
(55.3%) developed a post-operative complication compared with
the control group (48.8%) [adjusted odds ratio (OR) 1.12,
95%-CI 0.6–2.3,P = 0.761]. Patients of the conditioning group did
not suffer significantly more often from a grade IIIb to V compli-
cation than the control group (20.6% versus 12.8%; adjusted OR
0.84, 95%-CI 0.4–2.0, P = 0.688) (Table 3). The mortality rate was
similar in both groups (2.3% versus 4.3%, adjusted OR 0.63, 95%
CI 0.1–5.1, P = 0.668) (Table 3).
Discussion
The continuous application of the volatile anaesthetic sevoflurane
did not show a protection from I/R injury in liver surgery and
provided similar clinical outcomes as compared with the continu-
ous application of i.v. anaesthetic propofol.
Volatile anaesthetic agents attenuate cardiac mechanical dys-
function after ischaemia in the myocyte,24,25 and preserve hepatic
blood flow and cell function after ischaemia of the liver.26,27
Although i.v. anaesthetics such as propofol do not seem to have
Table 1 Patients' characteristics
Conditioning (n = 141) Control (n = 86)
Age (years), mean (SD) 59.2 (14.8) 56.3 (12.7)
Gender male/female (%) 88/53 (62.4%/37.6%) 49/37 (57%/43%)
ASA
median (IQR) 2 (2–3) 2 (2)
I&II (%) 87 (61.7%) 72 (83.7%)
III&IV (%) 54 (38.3%) 14 (16.3%)
Charlson, mean (SD) 5.1 (3.4) 6.0 (3.6)
Steatosis
30% 95 (67.4%) 49 (57.0%)
>30% 46 (32.6%) 37 (43%)
Fibrosis no/yes (%) 105/36 (74.5%/25.5%) 68/18 (79.1%/20.9%)
Pre-operative chemotherapy (%) 38 (27%) 39 (45.4%)
Malignant/benign disease (%) 106/35 (75.2%/24.8%) 70/16 (81.4%/18.6%)
Primary disease (%)
Echinococcosis 7 (5.0%) 3 (3.5%)
Colorectal metastasis 37 (26.2%) 36 (41.9%)
Neuroendocrine tumour 3 (2.1%) 2 (2.3%)
Hepatocellular carcinoma 27 (19.1%) 11 (12.8%)
Cholangiocarcinoma 19 (13.5%) 10 (11.6%)
Other benign lesions 26 (18.4%) 13 (15.1%)
Other malignant lesions 22 (15.6%) 11 (12.8%)
Baseline ALT (U/l), mean (SD) 63.4 (93.7) 51.9 (67.1)
Baseline AST(U/l), mean (SD) 50.1 (47.8) 45.7 (49.4)
Baseline bilirubin (mmol/l), mean (SD) 18.8 (37.8) 16.3 (30.8)
Conditioning, continuous volatile anaesthesia, control, continuous intravenous anaesthesia; ALT, alanine aminotranferease; AST, aspartate ami-
notransferase; ASA, American Society of Anesthesiologists; IQR, interquartile range; SD, standard deviation.
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Table 2 Intra- and post-operative parameters
Intra-operative Conditioning (n = 141) Control (n = 86)
Operation time (minutes), mean (SD) 289.1 (133.4) 279.6 (121.6)
Inflow occlusion (minutes), mean (SD) 35.5 (13.6) 33.4 (8.5)
Minor/major resection (%) 70/71 (49.7%/50.3%) 50/36 (58.1%/41.9%)
Central venous pressure (mmHg), mean (SD) 3.6 (2.9) 3.4 (2.5)
Post-operative outcome
Morbidity (%) 78 (55.3%) 42 (48.8%)
Mortality (%) 8 (5.7%) 2 (2.3%)
Post-operative complications
None complications 63 (44.7%) 44 (51.2%)
Grade I 10 (7.1%) 6 (7%)
Grade II 23 (16.3%) 17 (19.8%)
Grade IIIa 16 (11.3%) 8 (9.3%)
Grade IIIb 8 (5.7%) 3 (3.5%)
Grade IVa 10 (7.1%) 4 (4.6%)
Grade IVb 5 (3.5%) 2 (2.3%)
Grade V (30-days-mortality) 6 (4.3%) 2 (2.3%)
Conditioning, continuous volatile anaesthesia; control, continuous intravenous anaesthesia; SD, standard deviation.
Table 3 Primary and secondary outcome results
Outcome Conditioning
(n = 141)
Control
(n = 86)
Unadjusted difference
(95% CI, P-value)
Adjusted difference
(95% CI, P-value)
Peak AST, mean (SD)
U/l
629.0 (782.6) 592.5 (695.9) 36.52 (-158.26–231.30, P = 0.712) 61.85 (-151.66–275.38, P = 0.568)
Peak ALT, mean (SD)
U/l
615.2 (845.5) 554.1 (582.9) 61.11 (-124.87–247.09, P = 0.518) 136.06 (-113.77–385.90, P = 0.284)
Peak bilirubin, mean
(SD) mmol/l
56.2 (84.3) 46.15 (64.1) 10.00 (-7.59–27.60, P = 0.263) 9.40 (-15.79–34.58, P = 0.462)
Peak creatinine, mean
(SD) mmol/l
108.8 (56.8) 95.7 (47.7) 13.14 (-0.53–26.81, P = 0.060) -0.28 (-16.93–16.36, P = 0.973)
Blood loss, mean (SD) ml 491.5 (572.6) 396.4 (364.3) 455.46 (389.17–521.76, P = 0.001) 43.21 (-101.46–187.88, P = 0.557)
Length of hospital stay
in days, median (IQR)
12 (9–19) 11 (9–14) 2.97 (0.23–15.80, P = 0.034) 0.85 (-2.56–4.26, P = 0.622)
Length of ICU stay in
days, median (IQR)
1 (0–3) 0 2.16 (0.66–3.66, P = 0.005) 1.55 (-0.18–3.28, P = 0.079)
Unadjusted odds ratio
(95% CI, p value)
Adjusted odds ratio
(95% CI, p-value)
Any complication
(grade I–V) (%)
78 (55.3) 42 (48.8) 1.30 (0.77–2.18, P = 0.325) 1.12 (0.55–2.28, P = 0.761)
More severe complication
(grade IIIb–V) (%)
29 (20.6) 11 (12.8) 1.77 (0.85–3.7, P = 0.130) 0.84 (0.36–1.97, P = 0.688)
Mortality (%) 6 (4.3) 2 (2.3) 0.40 (0.08–1.91, P = 0.249) 0.63 (0.08–5.11, P = 0.668)
Conditioning, continuous volatile anaesthesia, control, continuous intravenous anaesthesia; ALT, alanine aminotranferease; AST, aspartate ami-
notransferase; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation; 95% CI, 95% confidence interval.
Adjusted for age, pre-operative chemotherapy (yes/no), steatosis (yes/no), ASA score, inflow occlusion time and baseline ALT/AST and bilirubin
level.
858 HPB
HPB 2012, 14, 854–862 © 2012 International Hepato-Pancreato-Biliary Association
comparable protective properties, they have been widely accepted
as they have the advantages of fast onset, a short recovery time
after the intervention as well as potentially less post-operative
nausea and vomiting.28
The literature describes the protective effects of volatile
anaesthetics upon pre-conditioning and post-conditioning
application.29–33 An anaesthetic preconditioning with volatile
anaesthetics such as sevoflurane was studied extensively in cardiac
surgery and could reveal a relevant protection of the I/R syndrome
in in vivo models34,35 as well as in RCTs.29 Additionally, volatile
anaesthetic post-conditioning protects the heart from I/R injury
in cardiac surgery in animal and in vitro models33,36,37 as well as in
a clinical trial.31 Furthermore, studies showed that the cardio-
protective effect during cardiac surgery could be related to the
dosage and/or duration of the application of volatile anaesthetics
in the pre- or post-conditioning setting38,39
For hepatic surgery, we demonstrated a beneficial effect of vola-
tile anaesthetics performing a pharmacological preconditioning
in our recently published RCT:1 application of sevoflurane for
10 min before the Pringle manoeuver resulted in lower peak
values of transaminases and, for the first time described in the
literature, also improved post-operative outcome with fewer com-
plications after liver resection. Additionally, we showed in a sub-
group analysis that patients with severe liver steatosis (30%) had
a stronger protective effect of the volatile anaesthetic precondi-
tioning on the I/R injury.1
After administration of continuous sevoflurane anaesthesia
(conditioning), patients undergoing coronary artery surgery
experienced a reduced myocardial damage as measured by cardiac
troponin I release, a reduced incidence of post-operative myocar-
dial infarction, less time on mechanical ventilation, a shorter
length of stay on the ICU as well as in the hospital.31,40,41 Therefore
the use of volatile anaesthetics as conditioning in cardiac surgery
is widely used and accepted,32,42 but in non-coronary surgical set-
tings it is contradictory as discussed.43 Nevertheless, based mainly
on data from studies performed in patients undergoing on-pump
coronary artery bypass surgery, the American College of Cardi-
ology and the American Heart Association Guidelines recom-
mended in 2007 the use of a continuous application of volatile
anaesthetics for non-cardiac surgery in patients at increased risk
of post-operative myocardial infarction.44 Interestingly, a recently
published RCT revealed that patients undergoing non-cardiac
surgery do not benefit from anaesthesia with volatile anaesthetics
compared with an i.v. anesthesia.45 In accordance with those
results from Zangrillo et al., our data in liver surgery also did not
demonstrate a protective effect of continuous application of vola-
tile anaesthetics.45 In the literature, two studies compared the
effects of a continuous application of either volatile or i.v. anaes-
thesics in liver surgery.46,47 Similar to our present results, Song
et al. also failed to present in a RCT any significant differences in
peak serum ALT/AST comparing patients with a continuous
application of volatile and i.v. anaesthesia during liver resection
with inflow occlusion.47 Although it was a randomized controlled
trial, they had a lower sample size (n = 100) than our present
study (n = 227), and did not adjust their results for steatosis.
In our present study we adjusted, amongst other well-known
confounders, our results for steatosis and thereby strengthen our
conclusion by minimizing the confounding effect. A further
interesting point is that Song et al. investigated the effect of
anaesthetics on I/R injury, but did not look at the effects of dif-
ferent anaesthetics on the clinical outcome such as morbidity or
mortality. We investigated the clinical outcome in both groups
and showed that neither continuous application of volatile nor
i.v. anaesthetics had a beneficial effect on the clinical outcome
focusing on any occurred complication, severe complications
(grade IIIb-V according to the Clavien-Dindo classification) or
30-days mortality.
In living related donors for liver transplantation, the post-
operative outcome was slightly improved after continuous appli-
cation of the volatile anaesthetic desflurane with a reduction
of minor complications such as a pleural effusion, wound
haematoma/seroma or hoarseness.46 Nevertheless, Ko et al. also
failed to demonstrate any significant differences in serum ALT/
AST levels or in severe complications.46 Yet this study cannot be
compared with our present study as inflow occlusion for a
minimum of half an hour was not applied in all of the patients,
and the patient population was different to our group. Living
donors for liver transplantation were healthy persons, whereas our
patient population had several additional significant factors influ-
encing the tolerance of I/R injury. For example, more than three-
quarters suffered from a malignant disease, and 35.8% received
pre-operative chemotherapy.
The mechanism of pharmacological and ischaemic precondi-
tioning in the liver is still unclear andmay be explained by numer-
ous possible pathways.1,48–52 A crucial factor might be the mode
and duration of application of volatile anaesthetics, inducing an
on-off phenomenon, which could be a prerequisite for hepatic
protection. During continuous application of sevoflurane such a
trigger might be missing.
One potential hypothesis strongly supported by our recently
published RCT,1 explaining the protective effect of pharmacologi-
cal preconditioning with volatile anaesthetics is the increased pro-
duction of nitric oxide (NO), demonstrated by the up-regulation
of the inducible (inflammatory) nitric oxide synthase (iNOS).1,51,52
NO is produced by NO-synthases and plays an important role in
the hepatic microcirculation by influencing the liver injury either
directly or by blood flow as a vasodilator.53–55 The literature sug-
gests another potential mechanism in preconditioning involving
the enzyme heme oxygenase (HO), which plays a crucial role in
the anti-oxidative system in nearly all organs including the
liver.56–58 There are three isoforms of HO enzymes and all three
degradation products have a protective function concerning I/R
injury.59 HO-1 can be up-regulated by volatile anaesthetics, espe-
cially isoflurane, and thereby the I/R injury of the liver can be
reduced after hepatic resection.60,61 However, we were unable to
assess this hypothetical pathway in this retrospective study
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because of a lack of liver tissue for further biochemical experi-
ments and examinations. Therefore, not only more experiments
in animals are required to clarify the pathway of the protective
effect of pharmacological preconditioning on remnant livers but
also further RCTs are also required to clarify the superiority or
equivalence of ischaemic preconditioning, or intermittent clamp-
ing concerning the attenuation of the I/R injury. Also, further
RCTs are required to investigate the effect of pharmacological
pre-conditioning and the continuous application of volatile
anaesthetics and its differences with regard to organ protection
and possibly improved outcomes.
Our study is limited by the lack of randomization with the
possibility of confounding by indication: (i) to control for con-
founding we adjusted our results for possible confounders such
as age, pre-operative chemotherapy (yes/no), steatosis (yes =
5%/no < 5%), ASA score, inflow occlusion time and baseline
AST/ALT and bilirubin levels, but we cannot exclude residual
confounding. (ii) A variety of confounding variables exist which
induce an inhibition (cyclooxygenase-2 inhibitors, non-steroidal
anti-inflammatory drugs) or an enhancement (opioids, statins)
of cardioprotection.62 They might also be of a certain importance
in liver patients, but were not evaluated. (iii) Another limitation
is the limited sample size, which led to rather imprecise esti-
mates. (iv) Furthermore, the higher 30-day mortality in the con-
ditioning group represented a negative selection bias in the sense
that continuous volatile anaesthesia was the preferred strategy
in patients with a compromised physical status, with multi-
morbidity, pre-existing liver dysfunction and/or planned major
surgery. This is reflected in Tables 2 and 3 and might explain the
rather high 30-day mortality rate in the conditioning group.
Although this study did not follow a prospectively outlined pro-
tocol, we consider the data to be of high quality as the database
of the Swiss HPB Center is based on prospectively collected data
from consecutive patients and tightly controlled by a database
manager.
Using sevoflurane for the entire anaesthesia, this study repre-
sents a different modality of sevoflurane application as the pre-
conditioning approach, used in our previous preconditioning
RCT, and results from the RCT are therefore not at all comparable
with the current data. This observation has also been made in a
prospective study in patients undergoing coronary surgery with
cardiopulmonary bypass. Sevoflurane preconditioning was com-
pared with sevoflurane post-conditioning and application of
sevoflurane for the surgical procedure. An apparent protection
was observed in one of the three groups only.31
In conclusion, the continuous application of the volatile anaes-
thetic sevoflurane during liver resection does not offer a protec-
tion of the remnant liver from I/R injury compared with the
continuous application of the i.v. anaesthetic propofol. These data
might also indicate that volatile anaesthetic-induced liver protec-
tion is triggered by an on-off mechanism such as pre- or post-
conditioning with no effect in a setup of continuous application of
volatile anaesthetics.
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